Annual Cash & Cash Equivalents
$4.71 M
-$1.80 M-27.64%
December 31, 2023
Summary
- As of February 7, 2025, PCSA annual cash & cash equivalents is $4.71 million, with the most recent change of -$1.80 million (-27.64%) on December 31, 2023.
- During the last 3 years, PCSA annual cash & cash equivalents has fallen by -$10.71 million (-69.47%).
- PCSA annual cash & cash equivalents is now -71.47% below its all-time high of $16.50 million, reached on December 31, 2021.
Performance
PCSA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$2.89 M
-$2.68 M-48.10%
September 30, 2024
Summary
- As of February 7, 2025, PCSA quarterly cash and cash equivalents is $2.89 million, with the most recent change of -$2.68 million (-48.10%) on September 30, 2024.
- Over the past year, PCSA quarterly cash and cash equivalents has dropped by -$6.03 million (-67.59%).
- PCSA quarterly cash and cash equivalents is now -87.45% below its all-time high of $23.05 million, reached on March 31, 2021.
Performance
PCSA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
PCSA Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -27.6% | -67.6% |
| 3 y3 years | -69.5% | -55.5% |
| 5 y5 years | +170.3% | -55.5% |
PCSA Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -71.5% | at low | -82.5% | at low |
| 5 y | 5-year | -71.5% | +580.6% | -87.5% | +1932.0% |
| alltime | all time | -71.5% | -100.0% | -87.5% | -100.0% |
Processa Pharmaceuticals Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $2.89 M(-48.1%) |
| Jun 2024 | - | $5.57 M(-37.5%) |
| Mar 2024 | - | $8.92 M(+89.5%) |
| Dec 2023 | $4.71 M(-27.6%) | $4.71 M(-31.4%) |
| Sep 2023 | - | $6.86 M(-20.9%) |
| Jun 2023 | - | $8.68 M(-19.2%) |
| Mar 2023 | - | $10.74 M(+65.2%) |
| Dec 2022 | $6.50 M(-60.6%) | $6.50 M(-28.2%) |
| Sep 2022 | - | $9.05 M(-24.9%) |
| Jun 2022 | - | $12.06 M(-16.2%) |
| Mar 2022 | - | $14.39 M(-12.7%) |
| Dec 2021 | $16.50 M(+7.0%) | $16.50 M(-13.6%) |
| Sep 2021 | - | $19.09 M(-8.3%) |
| Jun 2021 | - | $20.83 M(-9.6%) |
| Mar 2021 | - | $23.05 M(+49.5%) |
| Dec 2020 | $15.42 M(+2129.4%) | $15.42 M(+4637.6%) |
| Sep 2020 | - | $325.40 K(-28.1%) |
| Jun 2020 | - | $452.70 K(+218.1%) |
| Mar 2020 | - | $142.30 K(-79.4%) |
| Dec 2019 | $691.50 K(-60.3%) | $691.50 K(+37.1%) |
| Sep 2019 | - | $504.30 K(-30.2%) |
| Jun 2019 | - | $722.00 K(-42.2%) |
| Mar 2019 | - | $1.25 M(-28.3%) |
| Dec 2018 | $1.74 M | $1.74 M(-28.2%) |
| Sep 2018 | - | $2.42 M(-15.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2018 | - | $2.85 M(+60.4%) |
| Mar 2018 | - | $1.78 M(-37.6%) |
| Dec 2017 | $2.85 M(>+9900.0%) | $2.85 M(+3446.0%) |
| Sep 2017 | - | $80.30 K(+4126.3%) |
| Jun 2017 | - | $1900.00(+18.8%) |
| Mar 2017 | - | $1600.00(-50.0%) |
| Dec 2016 | $3200.00(+52.4%) | $3200.00(-52.2%) |
| Sep 2016 | - | $6700.00(-55.0%) |
| Jun 2016 | - | $14.90 K(+520.8%) |
| Mar 2016 | - | $2400.00(+14.3%) |
| Dec 2015 | $2100.00(>+9900.0%) | $2100.00(-86.1%) |
| Sep 2015 | - | $15.10 K(-0.7%) |
| Jun 2015 | - | $15.20 K(-63.6%) |
| Mar 2015 | - | $41.80 K(>+9900.0%) |
| Dec 2014 | $0.00(-100.0%) | $0.00(-100.0%) |
| Sep 2014 | - | $55.70 K(+39.6%) |
| Jun 2014 | - | $39.90 K(-51.5%) |
| Mar 2014 | - | $82.20 K(-56.0%) |
| Dec 2013 | $186.90 K(-81.7%) | $186.90 K(-81.3%) |
| Sep 2013 | - | $1.00 M(+59.1%) |
| Jun 2013 | - | $629.80 K(+49.4%) |
| Mar 2013 | - | $421.50 K(-58.7%) |
| Dec 2012 | $1.02 M(-63.5%) | $1.02 M(-26.6%) |
| Sep 2012 | - | $1.39 M |
| Dec 2011 | $2.79 M | - |
FAQ
- What is Processa Pharmaceuticals annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Processa Pharmaceuticals?
- What is Processa Pharmaceuticals annual cash & cash equivalents year-on-year change?
- What is Processa Pharmaceuticals quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Processa Pharmaceuticals?
- What is Processa Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
What is Processa Pharmaceuticals annual cash & cash equivalents?
The current annual cash & cash equivalents of PCSA is $4.71 M
What is the all time high annual cash & cash equivalents for Processa Pharmaceuticals?
Processa Pharmaceuticals all-time high annual cash & cash equivalents is $16.50 M
What is Processa Pharmaceuticals annual cash & cash equivalents year-on-year change?
Over the past year, PCSA annual cash & cash equivalents has changed by -$1.80 M (-27.64%)
What is Processa Pharmaceuticals quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of PCSA is $2.89 M
What is the all time high quarterly cash and cash equivalents for Processa Pharmaceuticals?
Processa Pharmaceuticals all-time high quarterly cash and cash equivalents is $23.05 M
What is Processa Pharmaceuticals quarterly cash and cash equivalents year-on-year change?
Over the past year, PCSA quarterly cash and cash equivalents has changed by -$6.03 M (-67.59%)